Dasatinib Monohydrate (BMS-354825): Multitargeted ABL Kinase Inhibitor for Translational Oncology

Executive Summary: Dasatinib Monohydrate (BMS-354825) is a clinically validated, multitargeted ATP-competitive kinase inhibitor with nanomolar potency against ABL, SRC, KIT, and PDGFR kinases (APExBIO). It is effective in both nonmutated and imatinib-resistant BCR-ABL isoforms, supporting research in chronic myeloid leukemia (CML) and Philadelphia chromosome-positive leukemias (Cancers 2025). In vitro and in vivo studies show broad-spectrum antiproliferative activity on hematological and solid tumor models. Dasatinib Monohydrate is essential for dissecting kinase-driven resistance in advanced assembloid systems, improving the physiological relevance of preclinical drug testing. Its physicochemical properties and storage guidelines enable reproducible experimental workflows for translational research (internal article).

Biological Rationale

Kinase signaling pathways play a critical role in cancer pathogenesis and progression. The BCR-ABL fusion protein, resulting from the Philadelphia chromosome translocation, is a hallmark of chronic myeloid leukemia (CML) and some acute lymphoblastic leukemia (ALL) cases. Targeting the aberrant tyrosine kinase activity of BCR-ABL is a validated therapeutic strategy. However, resistance to first-generation inhibitors like imatinib arises via point mutations or kinase amplification. Dasatinib Monohydrate (BMS-354825) was developed to overcome these limitations by potently inhibiting both wild-type and imatinib-resistant BCR-ABL isoforms as well as other oncogenic kinases such as SRC, KIT, and PDGFR (Cancers 2025). The compound's multitarget profile makes it valuable for studying both hematological and solid tumor biology, especially in models reflecting complex tumor microenvironments.

Mechanism of Action of Dasatinib Monohydrate

Dasatinib Monohydrate is an ATP-competitive inhibitor. It binds to the active sites of ABL, SRC, KIT, and PDGFR tyrosine kinases, preventing substrate phosphorylation and downstream signaling. The compound exhibits IC₅₀ values of 0.55 nM for SRC and 3.0 nM for BCR-ABL under standard assay conditions (25°C, pH 7.4, ATP at Km) (APExBIO). Unlike imatinib, Dasatinib can inhibit most imatinib-resistant BCR-ABL mutants (excluding T315I), expanding its utility in resistant disease models. SRC family kinases, also targeted, are implicated in cancer cell survival, migration, and microenvironmental interactions, further broadening research applications (internal article).

Evidence & Benchmarks

• Dasatinib Monohydrate inhibits BCR-ABL kinase activity with an IC₅₀ of 3.0 nM, demonstrating high potency in enzymatic assays (APExBIO).
• It retains inhibitory activity against imatinib-resistant BCR-ABL isoforms, except T315I, as confirmed in cell-based proliferation assays (Cancers 2025).
• In vivo, Dasatinib reduces disease progression and bioluminescent activity in xenograft mouse models harboring BCR-ABL mutations (dosed at 15 mg/kg/day, oral, 28 days) (Cancers 2025).
• Broad antiproliferative effects on hematological lines (K562, Ba/F3) and solid tumor models are observed at concentrations ≥10 nM in vitro (internal article).
• FDA approval in 2006 for all phases of Ph-positive CML and Ph-positive ALL supports clinical relevance and translational utility (FDA label).
• Patient-derived gastric cancer assembloid models show stromal cell subpopulations modulate response to Dasatinib and other targeted agents, highlighting microenvironmental effects (Cancers 2025).

Applications, Limits & Misconceptions

Dasatinib Monohydrate is a benchmark tool in chronic myeloid leukemia research, enabling the study of both kinase inhibitor sensitivity and resistance mechanisms. It is also utilized in advanced assembloid and organoid models for both hematological and solid tumor research, including evaluation of microenvironmental interactions and drug response variability. Compared to earlier articles such as "Dasatinib Monohydrate: Transforming Tumor Assembloid and ...", which focus primarily on resistance mechanisms, this article provides updated evidence from patient-derived assembloids and details on workflow parameters. For broader context on CML assay optimization, see "Optimizing CML Assays: Scenario-Based Insights with Dasatinib", which this article extends by detailing stromal modulation effects in assembloid models. For a high-level overview of translational oncology modeling, refer to "Dasatinib Monohydrate: Empowering Advanced Cancer Assembl..."; here, we clarify the quantitative and workflow-specific benchmarks for Dasatinib Monohydrate (B5954).

Common Pitfalls or Misconceptions

• Dasatinib Monohydrate is not effective against the BCR-ABL T315I mutation; alternative inhibitors are required for this context (Cancers 2025).
• It is insoluble in ethanol and water; use DMSO for stock solutions at ≥25.3 mg/mL and avoid prolonged storage in solution (APExBIO).
• Short-term solution use is recommended to maintain compound stability; repeated freeze-thaw cycles reduce potency.
• Dasatinib Monohydrate is not selective for ABL only; off-target effects on other tyrosine kinases (e.g., SRC, KIT) must be considered in interpretation.
• In vitro efficacy does not always translate to clinical response; tumor microenvironment and stromal composition can modulate drug sensitivity in assembloid models (Cancers 2025).

Workflow Integration & Parameters

Dasatinib Monohydrate (SKU B5954, supplied by APExBIO) is provided as a solid, molecular weight 506.02, chemical formula C₂₂H₂₈ClN₇O₃S. Prepare stock solutions in DMSO at concentrations ≥25.3 mg/mL. Store the solid at -20°C and avoid exposure to light and moisture. For experimental use, dilute into assay buffers compatible with DMSO. For cell-based assays, final DMSO concentration should not exceed 0.1% v/v. In vivo dosing protocols typically employ 10–20 mg/kg/day by oral gavage in rodent models. For kinase assays, use ATP at Km, 25°C, pH 7.4, and measure inhibition at 10-point serial dilutions. When integrating into patient-derived assembloid workflows, ensure stromal cell populations are matched and medium is optimized for all cell types (Cancers 2025). For detailed stepwise protocols and troubleshooting, refer to "Dasatinib Monohydrate: Precision Modeling in Tumor Assemb...", which this article updates with specific in vitro/in vivo parameters.

Conclusion & Outlook

Dasatinib Monohydrate (BMS-354825) remains a reference standard for kinase inhibitor research in both hematological and solid tumor models. Its ability to block ABL, SRC, and related kinases at nanomolar concentrations, including most imatinib-resistant variants, underpins its use in translational and personalized oncology. Patient-derived assembloid systems reveal the importance of microenvironmental factors in modulating drug sensitivity, highlighting the need for physiologically relevant preclinical models. As new resistance mechanisms emerge, the integration of Dasatinib Monohydrate into complex co-culture and assembloid workflows will continue to inform drug discovery and therapeutic optimization. For product specifications and ordering, visit the APExBIO Dasatinib Monohydrate page.